Concerning authorizing the governor to temporarily classify a substance as a controlled substance analog under schedule II.
Summary
SB 26-099 would give the governor temporary authority to classify a material, compound, mixture, or preparation as a controlled substance analog treated as a Schedule II controlled substance under Colorado law. The bill is aimed at synthetic drugs, especially fentanyl-related substances, that are chemically altered to evade existing drug schedules. It states that rapid changes in illicit drug chemistry can outpace the legislature’s ability to respond, creating public health and public safety risks and uncertainty in enforcement and prosecution.
Under the bill, the governor could issue an executive order designating a substance as a Schedule II analog if the substance is not already specifically excluded or included in a schedule, is substantially similar in chemical structure to a Schedule II drug or designed to produce a similar or greater effect, and is intended in whole or part for human consumption. The designation would require public and legislative notice, include a designation date, and automatically expire two years later unless repealed earlier. The bill also preserves the ability of courts to independently determine whether a substance is an analog, and allows the General Assembly to terminate a designation by joint resolution.
Impact
The bill would amend Colorado’s controlled substances law in section 18-18-204 to create a new temporary executive designation process for Schedule II analogs. If enacted, substances designated by the governor would be treated as controlled substances in Schedule II for purposes of Article 18, affecting criminal enforcement, prosecution, and related regulatory actions. The measure also adds procedural safeguards, including notice requirements, a two-year sunset on each designation, and legislative authority to end a designation, while explicitly preserving judicial review.
Sentiment
The bill’s stated purpose reflects strong concern about fentanyl and other synthetic opioids and a desire for faster state response to emerging drug threats. The legislative declaration frames the proposal as a narrowly tailored public safety tool intended to reduce confusion and inconsistency in the justice system. However, the bill was ultimately postponed indefinitely in the Senate Health & Human Services Committee, indicating that support was not sufficient to advance it and that concerns likely outweighed consensus at the committee stage.
Contention
The main point of contention is the delegation of authority to the governor to temporarily classify substances as controlled substance analogs, which raises separation-of-powers and due-process questions even though the bill includes limits and safeguards. Supporters appear to view the authority as necessary to keep pace with rapidly evolving synthetic drugs and to protect public health and safety. Potential critics may be concerned about executive overreach, the breadth of the analog standard, the impact on criminal liability, and whether temporary designations could create uncertainty for courts, law enforcement, and the public.